
HotSpot Therapeutics, a biotech firm, innovates allosteric therapies inspired by nature for novel disease treatment.
HotSpot Therapeutics, founded with a mission to harness nature's regulatory mechanisms to develop innovative therapies, focuses on pioneering allosteric drug discovery. By targeting "natural hotspots" on proteins, the company aims to create differentiated medicines that offer new treatment possibilities for various diseases. Their approach leverages the inherent on/off switches in proteins to modulate their function, representing a novel paradigm in biotechnology.
Notable figures associated with HotSpot Therapeutics include experienced biotech leaders and scientists who have significantly contributed to the field. The company has attracted substantial investment from leading venture capital firms, enabling it to advance its research and development efforts. Key achievements include the successful identification of multiple allosteric sites and the progression of several drug candidates into preclinical and clinical stages, underscoring its impact on the future of therapeutic innovation.

Bonum Therapeutics
bonumtx.com

Atavistik Bio
atavistikbio.com

Spotlight Therapeutics
spotlighttx.com

ProFound Therapeutics
profoundtx.com

Nested Therapeutics
nestedtx.com

Gain Therapeutics

Deep Apple Therapeutics
deepappletx.com

Algen Biotechnologies
algenbio.com

Alterome Therapeutics
alterome.com

Exo Therapeutics

Eikon Therapeutics
eikontx.com

Allogene Therapeutics
allogene.com

Faze Medicines
fazemed.com

Allyx Therapeutics
allyxthera.com

Quanta Therapeutics
quantatx.com
Companies similar to HotSpot Therapeutics include Bonum Therapeutics, Atavistik Bio, Spotlight Therapeutics and ProFound Therapeutics.
HotSpot Therapeutics was founded in 2017.
HotSpot Therapeutics' headquarters is located in Boston, MA, US.
HotSpot Therapeutics' most recent funding round was for $100M (USD) in November 2021.
As of Nov 29, 2021, HotSpot Therapeutics has raised a total of $210M (USD).
HotSpot Therapeutics has 91 employees as of Feb 4, 2024.